IQ Capital led a £70m Series A round in Trogenix.

IQ Capital, a venture capital firm engaged in investing in deep tech startups, supporting portfolio growth, and providing strategic guidance to early- and growth-stage technology companies, led a £70m Series A round in Trogenix, a biopharmaceutical company engaged in developing, manufacturing, and commercializing prescription medicines for central nervous system disorders and pain management, with participation from 4BIO Capital, Cancer Research Horizons, National Brain Tumor Society, Eli Lilly and Company, Meltwind, LongeVC, and Calculus Capital. “This significant investment accelerates our lead programme in glioblastoma and follow-on programme in colorectal cancer liver metastases through the clinic, advances our pipeline in liver and lung cancers, and further enhances our Odysseus® platform," Ken Macnamara, Trogenix CEO.